Jazz Pharmaceuticals (JAZZ)
(Real Time Quote from BATS)
$108.38 USD
-0.63 (-0.58%)
Updated Jul 22, 2024 11:52 AM ET
4-Sell of 5 4
A Value B Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
JAZZ 108.38 -0.63(-0.58%)
Will JAZZ be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for JAZZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JAZZ
Aurinia (AUPH) Soars 6.6%: Is Further Upside Left in the Stock?
Is The Options Market Predicting A Spike In JAZZ Pharmaceuticals (JAZZ) Stock?
JAZZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals
Why Is Jazz (JAZZ) Down 3.5% Since Last Earnings Report?
Other News for JAZZ
Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026
Buy Rating Upheld for Jazz Pharmaceuticals Amidst Potential for Growth and Strategic Revaluation
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024
Jazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer